


Nexus AG: VERY STRONG SALES AND EARNINGS INCREASE IN 2021


Donaueschingen, 08/03/2022: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by 15.5% and EBIT by 21.1% in the fiscal year 2021. As a result, the continually positive development of sales and earnings of the last years could be continued.



In 2021, sales improved from KEUR 162,944 to KEUR 188,178 (+15.5%). The "Healthcare Software" division increased its sales from KEUR 154,613 to KEUR 181,202 (+17.2%). The international share of total business volume was 45.2% (2020: 45.6%) and amounted to KEUR 85,134 compared to KEUR 74,333 (2020).

The consolidated earnings before interest and taxes (EBIT) rose very sharply by 21.1% to KEUR 24,114 (2020: KEUR 19,915), and EBITA rose by 18.9% from KEUR 24,284 (2020) to KEUR 28,872. EBITDA increased by 11.3% to KEUR 40,770 (2020: KEUR 36,640), and consolidated surplus increased by 15.7% to KEUR 17,459 (2020: KEUR 15,091).

Operating cash flow increased by 1.4% to KEUR 31,386 (2020: KEUR 30,947) and remains at a very high level. At the end of 2021, the company had cash resources at its disposal in the amount of KEUR 26,172 (31/12/2020: KEUR 26,449). Nexus AG had equity capital amounting to KEUR 142,403 as of 31/12/2021 (31/12/2020: KEUR 123,583). Consequently, the equity capital rate is 57.6% (31/12/2020: 55.4%). This demonstrates that Nexus AG has a sustainable and healthy balance sheet as well as sufficient capital for further financing of its European growth strategy. At the annual general meeting on 29/04/2022, the Supervisory Board and the Executive Board will propose to pay a dividend of EUR 0.20 per share.



The detailed Annual Report can be found on our homepage at: <https://en-en.nexus-ag.de/company/investor-relations/financial-reports>

About Nexus AG

Nexus AG develops and sells software solutions for the international healthcare market. With our core Hospital Information System (NEXUS / HIS) and integrated diagnostic modules (NEXUS / DIS), we have a unique product range, which can cover almost all functional requirements of hospitals, psychiatric institutions, rehabilitation facilities and diagnostic centers within our own product families. The focus of product development is on easy-to-use process support that increases efficiency and safety in patient treatment. NEXUS employs approx. 1,650 people, is present in seven European countries with its own sites and serves customers in an additional 23 countries via certified dealers. Thanks to continuously growing demand for NEXUS products, we have been able to build up a large customer base in recent years and regularly show increases in sales and results.